Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Victoria detects H5N1 avian influenza strain

It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Content from other channels on our network

interpack China to partner with AIP

Just a dash of protein enrichment for tomato sauce

AI is quietly reshaping retail and consumers may not even realise it

Protein washing: is it time to think beyond adding protein?

'Smart' packaging film developed to confirm food freshness

NSW EPA CEO takes on federal role

How does desalinated water help koalas?

Free cardboard drop-off service opens in Sydney's south-east

Protecting the environment is top reason people recycle: report

Govt solar scheme expansion reduces installation costs

"Migrant worker exploitation" sees NSW aged care provider repay nearly $120K

A Day in the Life of a birth suite ANUM

Professor Andrea Driscoll MACN wins 2026 Nursing Trailblazers Award

Do new AI models reproduce gender and racial stereotypes in medicine?

Small decisions. System-wide impact: Where sustainability and healthcare operations meet